MONOPAR THERAPEUTICS (MNPR): Price and Financial Metrics
MNPR Price/Volume Stats
| Current price | $0.68 | 52-week high | $1.75 |
| Prev. close | $0.66 | 52-week low | $0.27 |
| Day low | $0.66 | Volume | 77,500 |
| Day high | $0.72 | Avg. volume | 4,562,328 |
| 50-day MA | $0.72 | Dividend yield | N/A |
| 200-day MA | $0.57 | Market Cap | 11.83M |
MNPR Stock Price Chart Interactive Chart >
MONOPAR THERAPEUTICS (MNPR) Company Bio
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Latest MNPR News From Around the Web
Below are the latest news stories about MONOPAR THERAPEUTICS that investors may wish to consider to help them evaluate MNPR as an investment opportunity.
Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical ProgramsKey Developments and Financial Highlights for Investors |
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsMNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual MeetingWILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced third quarter 2023 financial results and summarized rece |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today! |
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingWILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later today at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, whic |
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceWILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar’s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference. Presentation Details: Date: October 12, 2023Time: 12:15 p.m. (ET)Location: The Yale Club, New York City, New York https://www.roth.com/conferences/upcom |
MNPR Price Returns
| 1-mo | -11.37% |
| 3-mo | 85.54% |
| 6-mo | 49.06% |
| 1-year | -44.72% |
| 3-year | -86.72% |
| 5-year | N/A |
| YTD | 99.88% |
| 2023 | -85.65% |
| 2022 | -26.17% |
| 2021 | -47.55% |
| 2020 | -63.13% |
| 2019 | N/A |
Loading social stream, please wait...